We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients from a well-defined area during the first 13 months of the pandemic. Sixty patients (median age 71 y, range 43–97) were identified. Median CIRS was eight (4–20). Patients had indolent CLL (n = 38), had completed (n = 12) or ongoing therapy (n = 10). Forty-six patients (77%) were hospitalized due to severe Covid-19 and 11 were admitted to ICU. Severe Covid-19 was equally distributed across subgroups irrespective of age, gender, BMI, CLL status except CIRS (p < 0.05). Fourteen patients (23%) died; age ≥75 y was the only significant risk factor (p < 0.05, multivariate analysis with limited power). Comparing month 1–6 vs 7–13 of the pandemic, deaths were numerically reduced from 32% to 18%, ICU admission from 37% to 15% whereas hospitalizations remained frequent (86% vs 71%). Seroconversion occurred in 33/40 patients (82%) and anti-SARS-CoV-2 antibodies were detectable at six and 12 months in 17/22 and 8/11 patients, respectively. Most (13/17) had neutralizing antibodies and 19/28 had antibodies in saliva. SARS-CoV-2-specific T-cells (ELISpot) were detected in 14/17 patients. Covid-19 continued to result in high admission even among consecutive and young early-stage CLL patients. A robust and durable B and/or T cell immunity was observed in most convalescents.

INTRODUCTION
Patients with chronic lymphocytic leukemia (CLL) have an increased risk of severe infections due to disease- and treatment-related immunodeficiency [1, 2] that does not exclude novel precision therapeutics such as ibrutinib [3, 4]. Two early international surveys reported that hospital-admitted Covid-19 patients with CLL had a high fatality rate [5, 6]. Understanding the full panorama of symptomatic Covid-19 infection in CLL requires analysis of consecutive patients from defined areas (i.e. without external referrals) identifying also those who were not admitted. This is particularly important since CLL patients may not respond sufficiently to Covid-19 vaccination [7, 8].

The present clinical immunological study included all CLL patients diagnosed with symptomatic Covid-19 during the first 13 months of the pandemic (March 2020-March 2021) in a well-defined geographical area (Stockholm, Sweden). Since diagnosis, follow-up and treatment of all CLL patients in our region is centralized to three hospitals and external referrals and office-based medicine are practically absent, we had a unique opportunity to identify all cases in order to generate reliable data on Covid-19 infection in the CLL population. We report here on their clinical outcome in two time periods of the pandemic (months 1-6 vs 7-13). In addition, we applied a panel of immune read-out methods to detect not only antibodies against SARS-CoV-2 but also their long-term persistence in convalescent serum. We investigated whether neutralizing antibody responses occurred (which may better correlate with protection) [9], if antibodies could be found in saliva and whether T cell immune response (IFN-gamma ELISpot assay) occurred in convalescents.

Received: 17 June 2021 Revised: 8 September 2021 Accepted: 13 September 2021
Published online: 25 September 2021
was determined using the mean + 6x SD of the 12 negative pre-pandemic samples as previously described [13].

**SARS-CoV-2 specific T cells**

T-cells specific for SARS-CoV-2 were analysed by IFN-gamma ELISPot assay as recently described [14]. Briefly, PBMC (2.5 x 10E5/well) were seeded in filter plates precoated with anti-IFN-gamma and supplemented with overlapping peptides spanning the immunogenic domains of the SARS-CoV-2 spike, membrane(M), nucleocapsid (N) and envelope (E) proteins, or control (Staphylococcal enterotoxin B (SEB)) peptides. Assays were incubated in duplicate for 24 h at 37 °C, washed and biotinylated anti-IFN-gamma was added and developed by addition of avidin and substrate. Spot-forming units (SFUs) were counted using an automated ELISPot reader system as previously described. Data are presented as number of spots/well, as % of CD3 T cells and as total numbers (IFN-gamma producing cells/μl). A patient was considered positive if > 20 SFUs with 5 and/or the M + N + E pool were recorded after background subtraction [14].

**Statistical Analysis**

All variables and analyses were pre-specified and selected from previous Covid-19 reports on large patient materials and mainly the 2 CLL publications [5, 6].

Data is summarized using descriptive statistics such as counts, percentages, medians and range. Categorical variables were expressed as cross-tabulations and distributional differences were tested using the Chi-squared test. Univariate and multivariate modelling of the outcome death (within three months) and hospitalization (yes, no) were performed using logistic regression. Variables included in the univariate analysis were sex, age (≥ 75 vs < 75) as in [5], BMI (≥ 25 vs < 25), diabetes (yes, no), CIRS (> 8 vs ≤ 8) based on our median, CLL treatment (never vs ever treated) as in [5], smoking status (never vs ever smoker) and hypogammaglobulinaemia. Variables without missing data were included in the multivariate analysis of both outcomes. Results from these models are reported as odds-ratios (OR) together with 95% confidence intervals (CI) and Wald p values. The fit of the multivariate models was evaluated using Pearson goodness-of-fit test. Stata version 17 was used for the statistical analysis. A numerical comparison of clinical outcome between month 1-6 vs 7-12 of the pandemic was also performed.

**RESULTS**

**Baseline characteristics**

During the first year of the pandemic (March 2020 – March 2021) we identified 60 patients with PCR-verified, symptomatic Covid-19 and CLL in our geographical region (Stockholm, Sweden). None had been vaccinated against SARS-CoV-2. Preliminary data from seven patients included in this study were previously reported in an international survey [5]. Five patients with previously unknown CLL were included as they were admitted due to severe Covid-19.

Baseline characteristics are shown in Table 1. The median age was 71 years (range 43-97) and 65% were men. Median CIRS was eight (range 4-20) and median BMI was 25 (range 19-42). Diabetes was present in 30% and 53% were never-smokers; only 3% were current smokers. Thirty-eight patients (63%) had indolent, untreated CLL, 12 (20%) had received prior anti-CLL therapy (all >12 months ago) and 10 patients (17%) had ongoing chemoimmunotherapy in 1, and venetoclax (+/- CD20 mAb in two patients) at the time of infection. Only 12% of the patients had progressive CLL and 2 patients received prophylactic (IV or SC) gammaglobulin therapy.

**Clinical outcome of Covid-19 infection**

Outcome results are summarized in Tables 1 and 2. Forty-six patients (77%) were hospitalized due to severe Covid-19 and 11 of them (24%) were admitted to ICU. The median length of hospitalization was 11 days (range 1-38) and at ICU 10 days (range 4-21). Severe Covid-19 was equally distributed across patient subgroups irrespective of age, gender, BMI, CLL status,
smoking status, diabetes and IgG level. CIRS (> 8 vs ≤ 8) was significantly associated with hospitalization in univariate and multivariate analysis (OR = 4.9, 95% CI:1.0–24.1, p = 0.048) (Suppl. Table S1). Death occurred in 14/60 patients (23%) and in 13/46 (28%) of those who had been hospitalized. Age ≥ 75 (vs < 75) years was significantly associated with death both in univariate and multivariate analysis (OR = 4.3, 95%CI:1.0–18.3,  p = 0.049) (Suppl. Table S2).

No other pre-specified subgroup analysis reached statistical significance but our statistical power was limited (n = 60).

Five patients had previously unknown CLL and may have caused a bias in the analysis. When re-analysing outcome on the remaining 55 patients the survival effect of old age remained significant in the univariate analysis (p = 0.04) but was no longer significant in the multivariate analysis (p = 0.07). The impact of CIRS on hospitalization was no longer significant in either analysis.

Table 1. Clinical characteristics in relation to hospitalization, ICU admission and death.

|                        | All patients (n = 60) | Requiring hospitalization (n = 46) | ICU admission (n = 11) | Death (n = 14) |
|------------------------|-----------------------|-----------------------------------|-----------------------|---------------|
| Median age, years (range) | 71 (43–97)            | 71 (43–97)                        | 71 (50–76)            | 81 (43–97)    |
| ≥75 y                  | 32% (19/60)           | 35% (16/46)                      | 18% (2/11)            | 57% (8/14)    |
| Male                   | 65% (39/60)           | 70% (32/46)                      | 64% (7/11)            | 64% (9/14)    |
| CIRS median (range) (n = 60) | 8 (4–20)             | 9 (4–20)                          | 8 (4–17)              | 10 (4–20)     |
| CIRS > 6               | 75% (45/60)           | 80% (37/46)                      | 73% (8/11)            | 86% (12/14)   |
| BMI, median (range) (n = 49) | 25 (19–42)          | 25 (20–42)                        | 25 (23–30)           | 24 (20–30)    |
| Diabetes               | 30% (18/60)           | 30% (14/46)                      | 36% (4/11)            | 14% (2/14)    |
| Never smoker           | 53% (31/59)           | 50% (23/46)                      | 45% (5/11)            | 50% (7/14)    |
| IgG (g/L), median (range) | 7.9 (2.1–13.4)       | 8.3 (2.1–13.4)                   | 8.3 (5.8–9.6)        | 5.4 (2.1–10.6) |

**CLL treatment at Covid-19 diagnosis (n = 60)**
- Never treated: 63% (38/60)
- Previously treated: 20% (12/60)
- Ongoing therapy: 17% (10/60)
- Current BTKi: 70% (7/10)

**CLL status at Covid-19 diagnosis (n = 60)**
- SD: 63% (38/60)
- CR/PR: 25% (15/60)
- PD: 12% (7/60)

Note: All >12 months ago.

Table 2. Outcome and management of Covid-19 among CLL patients (n = 60) in two time periods.

|                        | All patients | Admitted month 1–6 of the pandemic | Admitted month 7–13 of the pandemic |
|------------------------|--------------|-----------------------------------|-----------------------------------|
| Hospital admission     | 77% (46/60)  | 86% (19/22)                       | 71% (27/38)                       |
| ICU admission          | 24% (11/46)  | 37% (7/19)                        | 15% (4/27)                        |
| Death (if admitted)    | 28% (13/46)c | 32% (6/19)c                       | 26% (7/27)c                       |

**Intervention**
- Supplemental oxygen | 85% (39/46) | 84% (16/19) | 85% (23/27)
- Non-invasive ventilation (incl HFNO*) | 33% (15/46) | 37% (7/19) | 30% (8/27)
- Mechanical ventilation | 13% (6/46) | 32% (6/19) | 0% (0/27)
- IV vasopressors | 18% (8/45) | 32% (6/19) | 8% (2/26)
- Hemodialysis | 9% (4/46) | 11% (2/19) | 7% (2/27)

**Agents used for Covid-19**
- Hydroxychloroquine | 4% (2/45) | 11% (2/19) | 0% (0/26)
- Remdesivir | 26% (12/46) | 5% (1/19) | 41% (11/27)
- Tocilizumab | 2% (1/45) | 5% (1/19) | 0% (0/26)
- IVIG* | 4% (2/45) | 0% (0/19) | 8% (2/26)
- Corticosteroids | 65% (30/46) | 47% (9/19) | 78% (21/27)
- Convalescent plasma | 7% (3/46) | 5% (1/19) | 7% (2/27)
- Anticoagulation | 89% (41/46) | 84% (16/19) | 93% (25/27)

*High flow nasal oxygen.

Intravenous immunoglobulin.

Overall numerical death rate (including non-admitted patients) was 23% (32% in month 1–6 and 18% in month 7–13).
(both \( p = 0.07 \)). Forty-two of the 55 patients (76%) were hospitalized and 10 of them (24%) were admitted to ICU. Death occurred in 14/55 patients (25%).

Next, we compared numerically the risk of hospitalization, ICU admission and death, respectively, during the first 6 months of the pandemic vs month 7–13 (Table 2). Hospitalization due to severe Covid-19 was only slightly reduced in the second time period (from 86% to 71%) whereas ICU admissions among hospitalized patients were numerically reduced from 37% (7/19) to 15% (4/27). Almost all our patients were admitted as needed and received active therapy against the infection and its complications. One patient deferred intensive care and opted for palliation due to co-morbidities and advanced age. While overall death rates were numerically reduced from 32% (7/22) to 18% (7/38), fatalities among hospitalized patients were less reduced (from 32% (6/19) in period 1 to 26% (7/27) in period 2) but the number of events was limited and did not allow statistical comparisons. Details on Covid-19 treatment in time period 1 and 2 are depicted in Table 2. Supplemental oxygen was used in 85% confirming severe Covid-19 in admitted patients. In the second time period there was a numerical increase in the use of remdesivir (from 5% to 41%) but particularly corticosteroids became widely applied (from 47% to 78%). BTK inhibitor therapy was held in most patients during the infection. No long-term, post-covid complications were reported in surviving patients at 3, 6 or 12 months of follow-up.

**Immunological results**

Individual results are depicted in Table 3. Forty convalescent patients were tested at least once (month three and onwards) for antibodies against SARS-CoV-2 and 33 (82%) seroconverted in the sample taken at three or six months (Table 3). No baseline factor was significantly associated with seroconversion but the number of seronegative convalescents was low (\( n = 7 \)). Anti- SARS-CoV-2 antibodies were detectable in most patients tested at 6 months (17/22 patients) and at 12 months (8/11 patients) of follow-up.

We then performed in-depth immune analyses in some of the convalescents. The results are summarized in Table 3. First, a confirmatory serology test (IgG antibodies against Spike RBD and Core proteins) confirmed the results of screening assay (not shown). We thereafter applied a pseudoneutralizing assay and found that the antibodies from 13 of 17 patients had neutralizing capacity (Table 3), of which one patient was classified as seronegative in conventional serology. Next we analysed saliva (self-sampling kit) for the presence of anti- SARS-CoV-2 antibodies [13]. Twenty-eight patients were included in this analysis which was performed after median time of 6 months (range: 2–13); 19/28 (68%) had detectable salivary antibodies specific to the S1S2 spike trimer while 13 of them had salivary antibodies to the nucleocapsid (Suppl. Table S3). One patient (010) had antibodies in saliva without seroconversion. Finally we analysed T cell immunity against SARS-CoV-2 using a validated IFN-gamma ELISpot assay [14]. Among the 17 patients tested, 14 (82%) were positive (Table 3). The proportion and total number of SARS-CoV-2 specific T cells varied considerably between individuals. A positive T cell assay was generally paralleled by seroconversion which in some tested individuals was associated also with antibodies in saliva (triple positive patients) (Table 3). One patient (010) had strongly positive ELISpot results, negative blood serology tests but had antibodies in saliva.

**DISCUSSION**

Due to the combined effect of disease- and treatment-related immunodeficiency, patients with hematological malignancies may be at high risk for developing severe disease if infected by SARS-CoV-2 [15, 16]. Patients with CLL may be particularly vulnerable as indicated by two early international surveys reporting that more than one third of CLL patients had a fatal outcome if hospitalized due to Covid-19 [5, 6]. However, these reports included patients from various sources and were identified in the very beginning of the pandemic. Less severe cases were not included. To get a full picture of the Covid-19 panorama in patients with CLL, we conducted a thorough analysis of all patients with CLL who were diagnosed with Covid-19 in a well-defined geographical region (Stockholm, Sweden) where external referrals and office based-medicine are absent. Repeated check-up of the INCA database has verified that more than 95% of all CLL patients in our region are referred to/followed at our three hematology units. Thus, we were able to identify practically all symptomatic CLL patients who tested positive for SARS-CoV-2 RNA in our region, thereby getting as close as possible to reflect a real-world panorama of the incidence and outcome of symptomatic Covid-19 in patients with CLL.

Given the limitations mentioned above, we found that as many as 77% of consecutive CLL patients diagnosed with Covid-19 developed severe disease requiring hospitalization, and of these 28% died from Covid-19 and its complications. Thus, the risk of death, if hospitalized, was similar to the results shown in the early international surveys [5, 6]. We confirm that the death rate was significantly higher in patients 75 years or older [5]. Importantly, some patients were diagnosed with CLL as they were hospitalized due to severe Covid-19 infection. Including 5 patients with previously unknown CLL may represent a potential bias in our statistical analysis. The survival effect of old age remained significant in the univariate but not the multivariate analysis when these five patients were excluded. Another limitation of our study is that patients with mild Covid-19 and yet not detected/unknown CLL may have been missed as blood counts may not have been regularly checked in routine health care among otherwise healthy individuals with mild Covid-19. The number of patients (\( n = 60 \)) included provided limited power for multiple subgroup analyses. However, severe Covid-19 requiring hospitalization appeared to be similarly distributed across pre-defined subgroups irrespective of age, gender, BMI, diabetes, smoking, CLL status and hypogammaglobulinemia; comorbidities (CIRS) was the only significant risk factor. Of note, most patients diagnosed with Covid-19 were subject to hospital admission also during month 7–13 of the pandemic. ICU admittance and overall death rates declined numerically during the study period but the size of our study (\( n = 60 \)) did not allow a statistical comparison between the two time periods. Another potential limitation of our study is that the degree of aggressiveness in fighting the infection and its complications may have varied. However, palliation was applied in one patient only and the general level of active anti-Covid therapy was high in our region. Thus, a potential between patient variation in the intensity of anti-covid therapeutic efforts is unlikely to explain the differences observed over time.

The second aim of our study was to conduct an in-depth analysis of SARS-CoV-2 immunity and its long-term persistence in CLL convalescents. Since there is limited knowledge about post-covid immunity in CLL patients, we performed repeated testing of antibodies against SARS-CoV-2 in our cohort and in-depth immune analysis of some patients. More than 80% of our 40 tested convalescent patients had seroconverted, which is in line with the 67% seroconversion reported recently among 21 CLL patients [17]. In otherwise healthy (non-CLL) convalescents anti-Spike in plasma may decay rapidly [18]. Data from our longitudinal follow-up revealed that most tested patients were seropositive at 6 and even 12 months of follow-up. Furthermore, the antibodies detected in our patients had neutralizing capacity, which is assumed to correlate with protection [9]. By applying self-collecting saliva [13] we found that around two third of tested patients had detectable antibodies against spike in saliva. Mucosal antibodies secreted into saliva are thought to be important as it has been recently shown that the oral cavity and saliva are virus replication sites that actively participates in SARS-CoV-2 transmission [19]. Here, the frequency of saliva antibody-positive CLL patients is slightly lower than we recently reported for mild Covid-19 patients in a general population, in which specific saliva
Table 3. Immunological results in Covid-19 convalescent CLL patients.

| Patient number | Serologya | Neutralizing antibodies | Antibodies in Salivaa | ELSpot assay (IFN-gamma)id |
|---------------|-----------|--------------------------|-----------------------|---------------------------|
|               | 3 mo6 | 6 mo6 | 12 mo6 | Pos/Neg | Pos/Neg | Pos/Neg | Pos/Neg | Spike specific T cells/CD3+ (%) | Spike specific SFUs | Spike specific T cells/ul |
| 003           | Pos     | Pos   | Pos   | ++ (7) | Pos (13) | 0.09 | 44 | 1 | Pos (7) |
| 007           | Pos     | –     | Pos   | ++ (7) | Pos (13) | 0.2 | 46 | 3 | Pos (7) |
| 015           | –       | Pos   | –     | + + (5) | Pos (11) | 1.4 | 1032 | 59 | Pos (5) |
| 012           | Pos     | Pos   | Pos   | + (5) | Neg (10) | 0.35 | 380 | 1.5 | Pos (5) |
| 011           | Pos     | Pos   | Pos   | + + (6) | Pos (12) | 0.15 | 32 | 2 | Pos (6) |
| 024           | –       | Pos   | Pos   | + (8) | Neg (13) | 0.1 | 26 | 1.5 | Pos (8) |
| 014           | Pos     | Pos   | –     | + + (6) | – | 0.7 | 292 | 16 | Pos (6) |
| 017           | Pos     | Pos   | –     | + + (4) | – | 0.6 | 562 | 3.5 | Pos (4) |
| 030           | Pos     | Pos   | Pos   | + + (7) | – | 0.1 | 42 | 3.5 | Pos (7) |
| 020           | Pos     | Neg   | Neg   | Neg (8) | – | 0.5 | 456 | 4.5 | Pos (8) |
| 010           | Neg     | Neg   | Neg   | Neg (6) | Pos (12) | 2.2 | 2712 | 9.5 | Pos (6) |
| 013           | –       | Pos   | –     | + (5) | Pos (10) | 0.2 | 26 | 2.5 | Pos (5) |
| 023           | Pos     | Pos   | –     | + (3) | Pos (6) | 0.02 | 4 | 0.6 | Neg (3) |
| 009           | Neg     | Neg   | Neg   | Neg (7) | Neg (11) | 0.04 | 18 | 0.3 | Neg (7) |
| 006           | –       | Neg   | Pos   | Pos (9) | Pos (13) | 0 | 0 | 0 | Neg (9) |
| 052           | Pos     | Pos   | –     | – | Pos (4) | – | – | – | – |
| 058           | Pos     | –     | –     | – | Pos (3) | – | – | – | – |
| 060           | Pos     | Pos   | –     | – | Pos (4) | – | – | – | – |
| 043           | Pos     | Pos   | –     | – | Pos (6) | – | – | – | – |
| 019           | –       | Pos   | Pos   | + + (7) | Pos (12) | 0 | 0 | 0 | Pos (7) |
| 026           | Pos     | –     | –     | – | Neg (5) | – | – | – | – |
| 035           | Pos     | –     | –     | – | Pos (4) | – | – | – | – |
| 027           | Pos     | –     | –     | – | Neg (5) | – | – | – | – |
| 047           | Pos     | –     | –     | – | Pos (4) | – | – | – | – |
| 059           | Pos     | –     | –     | – | Neg (2) | – | – | – | – |
| 037           | –       | Pos   | –     | – | Pos (6) | – | – | – | – |
| 032           | Neg     | –     | –     | – | Neg (4) | – | – | – | – |
| 025           | Neg     | –     | –     | + (3) | Neg (6) | 0.15 | 32 | 4 | Pos (3) |
| 018           | Neg     | Neg   | –     | – | – | – | – | – | – |
| 036           | Pos     | –     | –     | – | – | – | – | – | – |
| 038           | Pos     | –     | –     | – | – | – | – | – | – |
| 044           | Pos     | –     | –     | – | – | – | – | – | – |
| 046           | Pos     | Pos   | –     | – | – | – | – | – | – |
| 051           | Neg     | –     | –     | – | – | – | – | – | – |
| 055           | Pos     | –     | –     | – | – | – | – | – | – |
| 057           | Pos     | –     | –     | – | – | – | – | – | – |
| 061           | Pos     | –     | –     | – | – | – | – | – | – |
| 062           | Pos     | –     | –     | – | Pos (3) | – | – | – | – |
| 034           | Pos     | –     | –     | – | Pos (3) | – | – | – | – |
| 029           | Neg     | –     | –     | – | – | – | – | – | – |
| 040           | –       | –     | –     | – | Pos (6) | – | – | – | – |
| 048           | Pos     | –     | –     | – | Neg (4) | – | – | – | – |

– no data available.
aNucleocapsid and/or spike – see Methods.
bNumber indicate time (months) from Covid-19 diagnosis to test.
cAntibody reactivity against the Spike S1S2 trimer. For MFI (median fluorescence intensity) value, see supplementary Table S3.
dELISpot was considered positive if >20 SFUs in Spike-based and/or M + N + E–based tests.
eNegative at 6 months against Nucleocapside, positive at 12 months against Spike.
fPositive due to 40 spots in the M + N + E analysis.
antibodies persisted in 88% (spike trimer) and 56% (capsid) in 9 months convalescence saliva [13]. In addition, we show that SARS-CoV-2 specific T cell immunity occurs in the majority of CLL convalescents which was usually but not always paralleled by seroconversion. This is in line with a recent report on 5 patients with antibody deficiencies [20] and a group of 22 patients with mixed hematological malignancies [15]. Whether T cell responses may occur also following Covid-19 vaccination in CLL is under investigation. Of note, T cell responses in healthy individuals were often more robust after vaccination than in convalescent patients [21]. A limitation of our immune analyses is that not all tests were performed and repeated in all patients. It appears however that durable responses including neutralizing antibodies occur in most CLL patients and that some of them also have antibodies in saliva and/or T cell immunity i.e. some patients were positive in two or three assays whereas others were positive in only one test. In a series of UK healthcare workers with mild or asymptomatic SARS-CoV-2 infection discordant neutralizing antibody and T cell responses were observed [22]. This demonstrates the complexity of the immune response to this virus making it challenging to compare immunity between infected patient groups. However, the humoral and cellular response pattern observed among CLL patients does not seem to differ significantly as compared to a population not affected by CLL, even though the magnitude appears to be lower than in otherwise healthy convalescents. Collectively, our immune results indicate that robust and durable B and/or T cell immunity may occur in most CLL patients following Covid-19 infection. Whether there is a common denominator for those few convalescent CLL patients who are completely negative in SARS-CoV-2 immune tests remains to be established. Our data suggest that the rate of seroconversion appears to be higher following natural infection in CLL patients than after Covid-19 vaccination [7, 8]. Patients who died from Covid-19 could not be included in the immune analysis which may at least partly explain why our rates on seroconversion appears higher than after de novo vaccination [7].

Whether convalescent CLL patients will benefit from booster vaccination is subject to an ongoing study.

REFERENCES

1. Langerbeins P, Eichhorst B. Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic. Acta Haematol. 2021;144:508–18.
2. Palma M, Gentilcore G, Heimersson K, Mozaffari F, Nasman-Glaser B, Young E, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102:562–72.
3. Mulder TA, Pena-Perez L, Berglov A, Meinke S, Estupinan HY, Heimersson K, et al. Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia. Hemasphere. 2021;5:e564.
4. Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. 2019;0:2527–30.
5. Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134–43.
6. Scarfo L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:3534–53.
7. Herishanu Y, Avivi I, Alaron A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:3534–53.
8. Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021;35:2703–5.
9. Khoury DS, Wheatley AK, Ramuta MD, Reynolds A, Cromer D, Subbarao K, et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol. 2020;20:727–38.
10. Kimby EAM, Mattsson M. First report from the Swedish CLL-registry: a nationwide registry with high coverage (Abstract XVI iwCLL Sydney). Leuk Lymphoma. 2015;56:42.

11. Parmelee PA, Thrues PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995;43:130–7.
12. Higgins V, Fabros A, Kulasigam V. Quantitative measurement of Anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol. 2021;59:e03149-20.
13. Alkhaaraa H, Bayati S, Hestholm C, Alemán S, Olsson A, Lindahl K, et al. Persisting Salivary IgA against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. J Infect Dis. 2021;224:407–14.
14. Sekine T, Perez-Pott A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183:158–168 e1114.
15. Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280–9.
16. Vijenthira A, Gong YJ, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.
17. Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047–9.
18. Anand SP, Prevost J, Nayrac M, Beaudoin-Bussieres G, Benlarbi M, Gasser R, et al. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset. Cell Rep. Med. 2021;2:100290.
19. Huang N, Perez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 2021;27:892–903.
20. Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate WJ, Lang H, Lazarски CA, et al. Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency. J Clin Immunol. 2021;41:1146–53.
21. Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, et al. SARS-CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv. 2021.
22. Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol. 2020;5:eabf3698.

ACKNOWLEDGEMENTS

We thank the patients who donated blood and saliva in this study. The technical assistance of Cecilie Hellström, Kaja Heinemarssen, Jennie Ollofsson, Eni Andersson, Lovisa Skoglund, Jamil Youssef, Anna Fahlen and Leila Relander is highly appreciated. Supported by grants from Swedish Blood Cancer Society, Swedish Cancer Foundation, Swedish Research Council, Erling Persson Family Foundation, Gilead Fellowship Award, Gunnar Grimfors Foundation, Knut and Alice Wallenberg Foundation and Region Stockholm.

AUTHOR CONTRIBUTIONS

LB, LH and AO designed the study, identified and met patients, analysed the data and wrote the manuscript. GB and SMu analysed and interpreted results and edited the manuscript. HU was the responsible statistician and performed statistical analyses and edited the manuscript. MB and YG analysed data, interpreted results and edited the manuscript. SH, MSC, KH, SMr, PN and EP analysed and interpreted results and edited the manuscript. LB and SH, KH and SMr, PN and EP analysed and interpreted results and edited the manuscript. SH, MSC, KH, SMr, PN and EP are the corresponding author. Correspondence and requests for materials should be addressed to Lotta Hansson.

COMPETING INTERESTS

The authors declare no competing financial interests. MB is a consultant for Oxford Immunotec.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41375-021-01424-w.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.